The termination removes a key catalyst for BioNTech's mRNA monotherapy thesis in CRC, an immunologically cold tumor. Monitor for full data analysis and any read-through to the ongoing PDAC combination trial. The stock may see pressure from this de-risking failure, but the broader oncology pipeline and COVID franchise provide a buffer.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 28 $102.08entry
- T+1 · 3mo ago −0.46%α −0.16% · $101.61
- T+5 · 2mo ago +1.65%α +1.54% · $103.76
- T+20 · 7w ago −3.48%α −3.99% · $98.52
- T+55 · todayOpen
- T+60 · in 6d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy in resected colorectal cancer after a DSMB recommendation citing a numerical overall survival imbalance and futility. The decision follows a prior futility boundary crossing in October 2025. The separate Phase 2 PDAC trial (IMcode003) combining autogene cevumeran with checkpoint inhibition continues unaffected. This is a meaningful pipeline setback for BioNTech's mRNA cancer immunotherapy platform in a key indication, though the company has multiple other oncology programs.
Key Facts
- BioNTech terminated Phase 2 trial BNT122-01 of autogene cevumeran in ctDNA-positive resected Stage II/III colorectal cancer.
- DSMB recommended termination after identifying a numerical imbalance in overall survival between treatment arms; no new safety signals.
- Futility boundary was crossed in October 2025 but DSMB deemed data immature at that time.
- The separate Phase 2 PDAC trial (IMcode003, NCT05968326) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy continues as planned.
- Autogene cevumeran is jointly developed with Genentech (Roche).
Financial Impact
Pipeline setback in colorectal cancer; no financial figures disclosed in filing. BioNTech has a $28B market cap with multiple other oncology programs.
Risk Factors
- Negative overall survival signal may raise questions about mRNA monotherapy efficacy in cold tumors.
- Potential for further pipeline delays or reprioritization if other monotherapy trials face similar challenges.
- Partner Genentech may reassess commitment to the mRNA cancer immunotherapy collaboration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000061 |
| Document: 0001776985-26-000061-index-headers.html | 0001776985-26-000061 |
| Document: 0001776985-26-000061-index.html | 0001776985-26-000061 |
| Document: 0001776985-26-000061.txt | 0001776985-26-000061 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers